Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 601–700 of 1,639
Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
Wang, W. T., Green, D. B., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Forst, B. J., Allam, M., Sarkis, P., Bcharah, G., Farina, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051108 · Cited by 9
“%] in the placebo group; p < 0.001) [16].”
InfluentialAdvances in Clinical Cardiology 2023: A Summary of Key Clinical Trials
Savage, P., Cox, B., Shahmohammadi, M., Kelly, B. P., & Menown, I. B. A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02877-y · Cited by 9
“There was no heterogeneity across LVEF groups [92].”
BackgroundNovel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 10
Yulong, X., Jiang, J., Fan, F., Pan, Y., Zhou, J., Zhang, Y., Li, J., Liu, J., Yang, N., Hao, Y., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033941 · Cited by 9
“13,14,29,30 However, during the period of CCC-AF, the above drugs may not be available in China or have not been recommended by HF guidelines.”
Heart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Harrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10410-0 · Cited by 6
The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF
Komić, L., Komic, J., Pavlović, N., Kumrić, M., Bukić, J., Tomić, I. J., & Božić, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020612 · Cited by 10
“In STEP-HFpEF, once-weekly semaglutide improved symptoms, exercise capacity, body composition, and inflammatory profiles in patients with obesity-related HFpEF [153].”
Chakravarthy, M. V., Rodríguez, R., Hergarden, A. C., Elliott, M. A., Frías, J. P., ARGÜELLES-TELLO, F. A., Tenorio, E., Rankin, J. E., Wu, J., Krishnan, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102291 · Cited by 8
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Abdul‐Hafez, H. A., Awashra, A., Bdir, S., Saife, S., Salah, Q., Barbarawi, M., Swaileh, T., Emara, A., Elgendy, M. S., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70152 · Cited by 9
“The magnitude of weight reduction approaches that seen after bariatric surgery in some series [1, 40].”
InfluentialGlucagon-like peptide-1 receptor agonists and aspiration risk
McIsaac, D. I., & Bryson, G. L. (2024) · BMJ · doi:10.1136/bmj.q1986 · Cited by 8
Borlaug, B. A., Chirinos, J. A., Lewis, G. D., Redfield, M. M., Bertoni, A. G., Cadeiras, M., Chiamvimonvat, N., Desai, A. S., Givertz, M. M., Kass, D. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102714 · Cited by 9
Self-citationAl-Dahi, W. A., Alenezi, A., Alessa, T., Alhamdan, R., Al-Humood, K., Alqallaf, A., AlOtaibi, T. M., AlRajab, H., Alshammari, A. M., Alyousef, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01838-0 · Cited by 9
“Semaglutide has also been proven as an effective treatment for patients with obesity‑related heart failure, improving symptoms, physical limitations, and exercise capacity even in those without diabe‑ tes [74, 75].”
Influential(2023) · Nature Medicine · doi:10.1038/s41591-023-02614-y · Cited by 7
Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
Dominic, K. L., Schmidt, A. V., Granzier, H. L. M., Campbell, K. S., & Stelzer, J. E. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1512550 · Cited by 9
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 9
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
Self-citationRetractedElangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
“…with obesity and HFpEF but without diabetes, the Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection (STEP-HFpEF) trial demonstrated that semaglutide significantly improved heart failure-related symptoms and exercise capacity compared to placebo 34 .”
Edwards, M., Thomas, M., FARR, M. A., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100114 · Cited by 6
Fueling the Heart: What Are the Optimal Dietary Strategies in Heart Failure?
Ataran, A., Pompian, A., Hajirezaei, H., Lodhi, R., & Javaheri, A. (2024) · Nutrients · doi:10.3390/nu16183157 · Cited by 7
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“14 There is also growing interest in the use of GLP-1 RAs for heart failure with preserved ejection fraction 15,16 given their effects on weight, inflammation, and hemodynamics.”
Grilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Zhang, Z., Wang, C., Liu, Q., Xiao, Y., Zhou, J., Wu, K., Huang, Y., Zhang, Z., Liu, S., & Lin, Q. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317721 · Cited by 6
Defining HFpEF in rodents: a systematic review
Adrah, Y., Hegemann, N., Faidel, D., Kucherenko, M. M., Kuebler, W. M., Schiattarella, G. G., Beyhoff, N., & Grune, J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf174 · Cited by 7
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 10
Köseoğlu, F. D., & Özlek, B. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131556 · Cited by 6
Devadoss, R., Dhillon, G. S., Sharma, P., Verma, R. K., Munjal, R. S., & Kashyap, R. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11010015 · Cited by 10
“The difference was notable after three STEP-HFpEF trial was the recent GLP-1 trial focusing on HFpEF, showing improvements in symptoms and exercise function [23]. months of treatment [21].”
BackgroundResponder Analyses Can Be Misleading
Southworth, M. R., Psotka, M. A., Pomeroy, J. E., & Stockbridge, N. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.017 · Cited by 6
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Khan, M. S., Dawood, M. H., Handelsman, Y., Anker, S. D., Coats, A. J. S., Green, J. B., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag201 · Cited by 9
Self-citationHeart failure with preserved ejection fraction therapeutics: in search of the pillars
Rafei, A. E., Harrington, J., Tavares, C. A. M., Guimarães, P. O., Ambrosy, A. P., Bonaca, M. P., Sauer, A. J., Vardeny, O., & Canonico, M. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10524-z · Cited by 8
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Thapa, R., Lara-Breitinger, K. M., López-Jiménez, F. A., Shama, N., Egbe, A. C., Miranda, W. R., Connolly, H. M., Jain, C. C., Jokhadar, M., Kosec, A. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101674 · Cited by 6
Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices
ELAD, B., Lee, C., Rahman, A., Rzechorzek, W., DeFilippis, E. M., Lotan, D., Moeller, C. M., Valledor, A. F., Rahman, S., Baranowska, J., et al. (2025) · Artificial Organs · doi:10.1111/aor.14942 · Cited by 6
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Suter, B., Rhodes, A. L., Bigeh, A., Frommeyer, T. C., & Mehta, L. S. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00761-0 · Cited by 8
“Numerous other trials have demonstrated positive cardiovascular outcomes with focus on HFpEF in the SUM-MIT trial for tirzepatide and the STEP-HFpEF trial for semaglutide [50–52].”
InfluentialA System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Fadel, L. P., Thao, G., Chitre, T., Rojas, E. D., Fricko, M. N., Domingo, V., Budginas, B., Guerrero, L. C., Ghatas, M., Arani, N. T., et al. (2025) · Cureus · doi:10.7759/cureus.78575 · Cited by 12
“%) in the placebo group [65].”
Research Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy
Yang, X., & Li, X. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm37180 · Cited by 6
“Subgroup analyses indicated that improvements in cardiac structural parameters—including left ventricular mass index and E/e’ ratio—were consistent regardless of the presence of T2DM [78].”
Wang, T.-Y., Zhang, L., Wang, H.-Y., & Jiang, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1725782 · Cited by 7
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Obesity Management for Patients with Coronary Artery Disease and Heart Failure
Syed, A. A., Adam, S., Miller, C., & Alkhaffaf, B. H. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.12.006 · Cited by 6
Sobral, M. V. S., Rodrigues, L. K., Barbosa, A. M. P., da Rocha, N. C., Moulaz, I. R., dos Santos, J. P. P., Oliveira, B. D. J. S., Moreira, J. L. D. M. L., Pacagnelli, F. L., & Guida, C. M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00721-4 · Cited by 7
“[15] Two studies were considered low risk [17, 18].”
Xu, B., Gaynor-Sodeifi, K., & Kundel, V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03312-6 · Cited by 6
Heart failure with preserved ejection fraction: implications for anaesthesia
Shah, A. M., Sabharwal, N. K., & Day, J. R. (2024) · BJA Education · doi:10.1016/j.bjae.2024.02.003 · Cited by 6
Metoyer, G. T., Whiteson, H. Z., Chen, Y., Li, Y., Gao, C., Menon, G., Bae, S., Lentine, K. L., Segev, D. L., McAdams‐DeMarco, M., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70354 · Cited by 7
Fawzy, A. M., Bisson, A., Lochon, L., Lenormand, T., Lip, G. Y. H., & Fauchier, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041044 · Cited by 5
Role of hypothalamus function in metabolic diseases and its potential mechanisms
Zhang, X., Yang, J., Li, Y., Li, Y., & Li, G. (2025) · PeerJ · doi:10.7717/peerj.19532 · Cited by 11
Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review
Othmane, T. E. H., Othmane, O. E. H., & Nizar, H. (2025) · Cureus · doi:10.7759/cureus.81512 · Cited by 15
“Personalized treatments targeting specific metabolic abnormalities, such as SGLT2 inhibitors for insulin resistance or GLP-1 agonists for weight loss, may improve cardiac function and slow disease progression [62,63,86].”
Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future
Das, B. B. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44109 · Cited by 6
Zebrowska, A. M., & Borowiec, A. (2025) · Pharmaceuticals · doi:10.3390/ph18060857 · Cited by 5
“In the STEP-HFpEF trial, semaglutide improved outcomes in patients with heart failure with preserved ejection fraction (HFpEF), leading to greater improvements in exercise capacity compared to the placebo [90].”
From obesity to cardiovascular disease: pathological basis and clinical implications
Nardin, M., Mehran, R., Oliva, A., Kedhi, E., Galasso, G., Nardin, S., Savonitto, S., Condorelli, G., & Luca, G. D. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.04.041 · Cited by 7
Dorta, E. R., Wolf, A., Hübscher, A., Blaschke, D., Seeland, U., Crayen, C., Bischoff, S., Mattig, I., Dreger, H., Stangl, K., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1242805 · Cited by 8
“In the same line, the bene fi cial clinical impact of drug-induced weight reduction using semaglutide in patients with already diagnosed heart failure with preserved ejection fraction, as recently published by the authors of the STEP-HFpEF Trial (40), highlights the importance of routinely implementing early cardiovasc…”
BackgroundSotagliflozin: Two Birds with One Stone?
Requena-Ibáñez, J. A., Kindberg, K. M., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07723-z · Cited by 7
Smetana, G. W., Ho, J. E., Orkaby, A. R., & Reynolds, E. E. (2023) · Annals of Internal Medicine · doi:10.7326/m23-2384 · Cited by 5
“A major area of interest is the evolving landscape of medical therapies for obesity with glucagon-like peptide-1 receptor agonists, with 2 current HFpEF trials published or under way (10, 11).”
BackgroundAlbani, S., Zilio, F., Scicchitano, P., Musella, F., Ceriello, L., Marini, M., Gori, M., Khoury, G., D’Andrea, A., Campana, M., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.09.013 · Cited by 8
Type 2 diabetes, heart failure and the treatment of their comorbidity
Wang, S., & Li, S. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09264-4 · Cited by 6
Li, Y., Wang, C., Hung, C., Wu, Y., Hsu, C., Tsou, Y., Wang, C., Wu, C., Lin, P., Chang, H., et al. (2024) · PubMed Central · doi:10.6515/acs.202403_40(2).20240206a · Cited by 15
Trenas, A., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., Gómez‐Doblas, J. J., Martínez-Esteban, M. D., Bouarich, O., García‐Casares, N., Fernández‐García, D., de Lucas, M.-D. G., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.007 · Cited by 6
Management of patients with heart failure and chronic kidney disease
Wu, L., Rodríguez, M., Hachem, K. E., Tang, W. H. W., & Krittanawong, C. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10415-9 · Cited by 6
“It showed semaglutide was associated with significant weight loss, improved heart failure-related symptoms, and a longer 6-min walk distance at 52 weeks [135].”
The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Cannon, C. P., & Marx, N. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae112 · Cited by 6
Joo, J. H., Zhao, A., Chalasani, M., Allan, K. C., & Rachitskaya, A. V. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.12.014 · Cited by 6
Mihăilă, M.-D., Caloian, B., Frîngu, F. I., Irimie, D. A., Minciună, I., & Pop, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176139 · Cited by 8
“The STEP-HFpEF trial linked semaglutide to improved symptoms, lower NT-proBNP/CRP levels, and fewer adjudicated events in obese HFpEF, supporting the idea that EAT modulation, not weight loss alone, underpins cardiovascular benefit [129].”
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
“…ratio: 0.82 (95% CI, 0.74–0.91; p = 0.0002) [96] KCCQ-CSS, 7.8 points (95% CI, 4.8–10.9; p < 0.001) [87] 20.3 m (95% CI, 8.6–32.1; p < 0.001) [87] Dapagliflozin -3.5 kg (95% CI, -5.9 to -1.1; p = 0.006) [114] Geometric mean ratio: 0.92 (95% CI, 0.88–0.96) [115] KCCQ-TSS, 3.7 points (95% CI,…”
InfluentialKachmar, M., Corpodean, F., Popiv, I., LaPenna, K. B., Danos, D., Cook, M. W., Saunders, B. A., Domercant, J. J., Albaugh, V. L., & Schauer, P. R. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01798-2 · Cited by 6
What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives
Sabouret, P. F., Ecarnot, F., Rosa, S. D., & Ray, K. K. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad632 · Cited by 6
Obesity and Comorbidities in HFpEF: A Retrospective Cohort Analysis in a University Hospital Setting
Hobbach, A. J., Brix, T. J., Weyer‐Elberich, V., Varghese, J., Reinecke, H., & Linke, W. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103348 · Cited by 5
“…peptide-1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists, may offer new therapeutic avenues for obese patients with HFpEF, especially women who are disproportionately affected and often represent a distinct clinical cluster population [26–28].”
Bile acids for diabetic cardiomyopathy
Weissman, D., & Maack, C. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01032-9 · Cited by 5
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
“Recent evidence suggests GLP-1 RAs bene fi t patients with HFpEF 77,78 .”
Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5
“Similarly, the STEP-HFpEF trials [33, 34] showed that treatment with semaglutide led to weight loss and improvements in functional capacity, cardiac biomarkers, and quality of life in patients with obesity and heart failure with pre-served ejection fraction.”
Li, A. C.-W., Lin, Y.-C., Huang, J., Chen, L.-C., & Chua, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326534 · Cited by 10
“In 2023, the STEP-HFpEF trial showed that semaglutide, a once-weekly long-acting GLP-1 RAs, significantly improved exercise capacity, enhanced quality of life, and notably reduced body weight while mitigating inflammation over 52 weeks in obese patients with HFpEF compared to placebo [9].”
InfluentialNon-cardiac comorbidities in heart failure: an update on diagnostic and management strategies
Kodur, N., & Tang, W. H. W. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09070-0 · Cited by 6
The evolving role of metabolic and bariatric surgery in contemporary clinical practice
Panichella, G., Gentile, F., Nannipieri, M., & Emdin, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf787 · Cited by 6
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
“79,80,89,90 From a pragmatic standpoint, it is difficult to argue against the use of GLP-1–based therapy as first-line treatment in patients with MASH who also have over-weight, obesity, and/or type 2 diabetes, if no contraindications exist.”
Cardio-Renal Syndrome: Review and New Perspectives
Martín, M., Fernández, M., Bacigalupe, L. P., & Rozado, J. (2026) · Journal of CardioRenal Medicine · doi:10.3390/jcrm2010004 · Cited by 7
Aortic Stenosis and Heart Failure with Preserved Ejection Fraction: A Shared Phenotypic Puzzle
Scotti, A., Slipczuk, L. N., & Latib, A. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3050 · Cited by 5
Miyamoto, K., Jones, X. M., Yamaguchi, S., Ciullo, A., Li, C., Coto, J. G., Tsi, K., Anderson, J., Morris, A. A., Marbán, E., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01095-5 · Cited by 6
“The only drug classes shown to be effective in HFpEF to date are the SGLT2 inhibitors and GLP1 agonists, and even they are limited in efficacy, insofar as mortality is not decreased, at least not in the trials reported to date [1, 4, 5, 12, 19].”
Foulkes, S., Ferreira, S. M., Milani, M., Bekhuis, Y., Falter, M., Delpire, B., Pauwels, R., Stroobants, S., Jogani, S., Vanhentenrijk, S., et al. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00587.2025 · Cited by 5
Kozaily, E., Akdogan, R. E., Dorsey, N. S., & Tedford, R. J. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01296-2 · Cited by 6
“The use of drug therapy in addressing obesity in HFpEF was cemented in the recently published randomized, double-blind, placebo-controlled STEP-HFpEF [56].”
Renal Denervation in Heart Failure Treatment: Data for a Self-Fulfilling Prophecy
Dimitriadis, K. S., Iliakis, P., Pyrpyris, N., Tatakis, F., Fragoulis, C., Mantziaris, V., Plaitis, A., Beneki, E., Tsioufis, P., Hering, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226656 · Cited by 5
Kobe, E. A., Thakkar, A., Matai, S., Akkaya, E., Pagidipati, N. J., McGarrah, R. W., Bloomfield, G. S., & Shah, N. P. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100888 · Cited by 9
Antagonizing HFpEF by Targeting Fibrosis
Garry, G. A. (2025) · Circulation · doi:10.1161/circulationaha.124.072973 · Cited by 5
Heinen, A., Spychala, A., Ballmann, L., Gödecke, S., Faradj, Z., Bresch, F., Krüger, M., Bottermann, K., Zabri, H., Fischer, J. W., et al. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00843.2025 · Cited by 6
Hathorn, B., Haykowsky, M. J., Almandoz, J. P., Pandey, A., Sarma, S., Hearon, C. M., Babb, T. G., Balmain, B. N., Fu, Q., Zaha, V. G., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.015 · Cited by 9
Semaglutide attenuates neuroinflammation in male mice
Rausch, D. M., Ludwig, M. Q., Bentsen, M. A., Hansen, S. N., Secher, A., Holst, D., Moreno, J., Das, V., Egerod, K. L., Bjerregaard, A.-M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74038-4 · Cited by 10
“8, Supplementary Data 3).”
InfluentialA Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
“The change in HF symptoms with semaglutide was comparable between patients with obesity-related HF alone and those with concomitant T2DM [204,205].”
Influence of Obesity on Invasive Hemodynamics and Prognosis in Patients With Heart Failure
Hansen, B. L., Deis, T., Larsson, J. E., Ersbøll, M. K., Rossing, K., Schou, M., Lim, H. S., & Gustafsson, F. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.12.009 · Cited by 7
Self-citationMeddeb, M., Koleini, N., Jun, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.09.598152 · Cited by 5
Self-citationVelasco, M. Á. P., Trenas, A., Bernal-López, M. R., de Lucas, M. D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.12.008 · Cited by 5
Kazé, A. D., Bertoni, A. G., Fox, E. R., Hall, M. E., Mentz, R. J., & Echouffo-Tcheugui, J. B. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3447 · Cited by 6
“53,54 Our study also underscores the need for further research exploring the biological mechanisms underlying the associations of adverse metabolic health and HF risk, thus potentially providing new therapeutic targets.”
Yuasa, N., Harada, T., Kagami, K., Ishii, H., & Obokata, M. (2024) · Journal of Medical Ultrasonics · doi:10.1007/s10396-024-01468-2 · Cited by 5
“The increasing proportion of individuals with HFpEF and the emergence of effective disease-modifying therapies, such as SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists, makes the accurate and timely identification of HFpEF even more important [68–70].”
Convergent Metabolic Pathways in MASH Therapeutics: An AMPK ‐Centric Analysis
Choi, S., Jung, J., Seo, Y., Song, S., Ham, J., Chung, H., Ramadan, Y., & Choi, K. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71023 · Cited by 6
“They increase insulin secretion that depends on glucose, stop glucagon release and most importantly, they lower appetite, which can lead to a lot of weight loss (often 10%–15% of body weight with high-dose semaglutide) [69].”
Schauer, A., Jahn, D., Vahle, B., Barthel, P., Männel, A., Fabig, G., Linke, A. H.-P., Adams, V., & Augstein, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021060 · Cited by 5
“Characterized by high prevalence, significant morbidity, and limited effective therapeutic options, sodium– glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown some clinical benefit [2,3].”
Semaglutide: A New Medical Swiss Army Knife?
Marijic, J., & Neelankavil, J. P. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.12.032 · Cited by 5
Conde, A. C., Martínez, J. J. G., Teruel, J. L., Lorite, N. M., Marcos, M. C., Freixa‐Pamias, R., Obaya, J. C., Hermida, Á. B. Á., Ruíz, R. C., Olmo, R. F., et al. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.04.003 · Cited by 9
Hegner, P., Baier, M. J., Krammer, T., Seitz, S., Käs, A.-K., Zschiedrich, T., Lukas, D., Lutz, V., Wolf, M., Sinha, F., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag039 · Cited by 5
Velasco, M. Á. P., Bernal-López, M. R., Trenas, A., Ricci, M., Lopez-Carmona, M. D., de Lucas, M.-D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107019 · Cited by 5
Can Semaglutide offer hope for patients with obesity-related heart failure?
Olatunji, G. D., Aderinto, N., Kokori, E., Ogieuhi, I. J., Abraham, I. C., Olanisa, O., Nebuwa, C. N., Awoyinfa, M., Ajimotokan, O. I., Ajayi, J. O., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102697 · Cited by 4
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“31,32 While part of this benefit likely reflects weight loss, mediation analyses suggest that associated improvements in glycemia, blood pressure, and lipid profile account for only a fraction of the observed cardiovascular effect.”
Effect of GLP‐1 Receptor Agonists on Post‐Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis
Shubietah, A. R. M., Elgendy, M. S., Awashra, A., Murad, M. R., Alqudah, M., Gowaily, I., Mohamed, A. A., Emara, A., Olumuyide, E. O., Elbataa, A., et al. (2026) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.70262 · Cited by 6
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“[89] and STEP HFpEF DM [90] showed that treatment with semaglutide led to a reduction in heart failure events, NT-proBNP and CRP levels, as well as an improvement in 6-min walking distance (6MWD) and Kansas City Cardiomyopathy (KCCQ) scores in patients with confirmed HFpEF and the obesity…”
Self-citationSillassen, C. D. B., Kamp, C. B., Petersen, J. J., Faltermeier, P., Siddiqui, F., Grand, J., Domínguez, H., Frølich, A., Gæde, P., Gluud, C. N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084190 · Cited by 11
“…versus placebo (the ‘Semaglu-tide Effects on Cardiovascular Outcomes in People With Overweight or Obesity’ (SELECT) trial 17 and the ‘Sema-glutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity’ (STEP-HFpEF) trial 18 ) have not been included in the previous reviews.”
Background
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.